GSK plc (NYSE:GSK) Shares Bought by Forum Financial Management LP

Forum Financial Management LP grew its stake in GSK plc (NYSE:GSK - Free Report) by 167.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,397 shares of the pharmaceutical company's stock after acquiring an additional 8,396 shares during the quarter. Forum Financial Management LP's holdings in GSK were worth $453,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GSK. Stock Yards Bank & Trust Co. acquired a new position in shares of GSK in the 3rd quarter valued at $210,000. World Investment Advisors LLC acquired a new position in GSK during the third quarter worth $421,000. Wilmington Savings Fund Society FSB purchased a new position in shares of GSK during the third quarter worth $787,000. Optimist Retirement Group LLC grew its stake in shares of GSK by 3.7% in the third quarter. Optimist Retirement Group LLC now owns 49,554 shares of the pharmaceutical company's stock valued at $2,026,000 after buying an additional 1,790 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of GSK by 8.6% in the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company's stock valued at $9,052,000 after buying an additional 18,539 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on GSK shares. BNP Paribas started coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Finally, Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Eight analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Stock Down 0.2 %

Shares of GSK traded down $0.08 during midday trading on Friday, reaching $37.42. The stock had a trading volume of 3,909,251 shares, compared to its average volume of 4,704,553. The company has a market cap of $77.21 billion, a price-to-earnings ratio of 23.53, a PEG ratio of 1.12 and a beta of 0.56. The company's fifty day simple moving average is $37.50 and its two-hundred day simple moving average is $36.05. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were issued a $0.3932 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.20%. GSK's dividend payout ratio is presently 100.63%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.